Bg pattern

ROPIVACAINE READYFUSOR 2 mg/mL SOLUTION FOR INFUSION IN ADMINISTRATION SYSTEM

Prescription review online

Prescription review online

A doctor will review your case and decide whether a prescription is medically appropriate.

Talk to a doctor about this medicine

Talk to a doctor about this medicine

Discuss your symptoms and possible next steps in a quick online consultation.

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use ROPIVACAINE READYFUSOR 2 mg/mL SOLUTION FOR INFUSION IN ADMINISTRATION SYSTEM

Translated with AI

This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.

Show original

Introduction

Package Leaflet: Information for the User

Ropivacaína Readyfusor 2 mg/ml solution for infusion in administration system

ropivacaína, hydrochloride

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

  • Keep this leaflet, you may need to read it again.
  • If you have any further questions, ask your doctor or nurse.
  • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
  • If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

Contents of the pack:

  1. What Ropivacaína Readyfusor is and what it is used for
  2. What you need to know before you use Ropivacaína Readyfusor
  3. How to use Ropivacaína Readyfusor
  4. Possible side effects
  5. Storage of Ropivacaína Readyfusor
  6. Contents of the pack and other information

1. What Ropivacaína Readyfusor is and what it is used for

The name of your medicine is “Ropivacaína Readyfusor 2 mg/ml solution for infusion in administration system”. It contains the active substance called ropivacaína hydrochloride which belongs to a class of medicines called local anesthetics.

Ropivacaína Readyfusor is used in adults for the treatment of acute pain. It numbs (anesthetizes) a part of the body, for example, after surgery.

Doctor consultation

Not sure if this medicine is right for you?

Discuss your symptoms and treatment with a doctor online.

2. What you need to know before you use Ropivacaína Readyfusor

Do not use Ropivacaína Readyfusor

  • if you are allergic to ropivacaína hydrochloride or any of the other ingredients of this medicine (listed in section 6).
  • if you are allergic to any other local anesthetic of the same class (such as lidocaine or bupivacaine).
  • if you have a reduced blood volume (hypovolemia).
  • to inject it into a blood vessel, spinal column or joint to numb a specific area of your body, or into the neck of the uterus to relieve pain during childbirth.

If you are not sure if any of the above applies to you, tell your doctor before using Ropivacaína Readyfusor.

Warnings and precautions

Tell your doctor or nurse before using Ropivacaína Readyfusor, especially:

  • if you have heart, liver or kidney problems
  • if you have a rare blood pigment disease called “porphyria” or if someone in your family has it, as your doctor may need to use a different medicine
  • if you have any other illness or medical condition.

Using Ropivacaína Readyfusor with other medicines

Tell your doctor if you are using or have recently used other medicines. This is because Ropivacaína Readyfusor may affect the action of some medicines and some medicines may have an effect on Ropivacaína Readyfusor.

In particular, tell your doctor if you are taking any of the following medicines:

  • Other local anesthetics
  • Strong painkillers, such as morphine or codeine
  • Medicines used to treat irregular heartbeats (arrhythmia), such as lidocaine and mexiletine.

Your doctor should know that you are using these medicines to decide if Ropivacaína Readyfusor can be given to you.

Tell your doctor if you are taking any of the following medicines:

  • Medicines used to treat depression (e.g. fluvoxamine)
  • Antibiotics to treat bacterial infections (e.g. enoxacin).

This is because your body needs more time to eliminate Ropivacaína Readyfusor if you are taking these medicines.

If you are taking any of these medicines, you should avoid prolonged use of Ropivacaína Readyfusor.

Pregnancy and breastfeeding

If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before using this medicine.

It is not known if ropivacaína hydrochloride affects pregnancy or if it passes into breast milk.

As a precaution, it is recommended to avoid using Ropivacaína Readyfusor during pregnancy.

During treatment with Ropivacaína Readyfusor, breastfeeding should be temporarily stopped. During this period, milk should be expressed and discarded.

Driving and using machines

Ropivacaína Readyfusor may make you feel drowsy and affect your reaction speed. After using Ropivacaína Readyfusor, you should not drive or use tools or machines until the next day.

Ropivacaína Readyfusor contains sodium

This medicine contains 3.4 mg of sodium (main component of cooking/table salt) per milliliter. This is equivalent to 0.17% of the maximum recommended daily sodium intake for an adult.

3. How to use Ropivacaína Readyfusor

Ropivacaína Readyfusor will be given to you by a doctor.

Ropivacaína Readyfusor will be administered by infusion to reduce pain after surgery. It will be administered near a nerve (perineurally) or in a surgical wound (infiltration). For wound infiltration, your doctor will place a catheter in the wound during surgery, which can be connected to the Ropivacaína Readyfusor infusion pump (hereinafter referred to as the “dispenser”).

The dispenser is a device that contains the infusion solution and has a catheter with a permanent connector that can be connected to the catheter placed in the wound or near the nerve.

Your doctor or nurse will activate the dispenser and connect it to the catheter/access route. You will not have to do anything with the dispenser.

After activation, the dispenser will continuously administer a defined dose of the active substance, sufficient for pain relief.

Warnings

  • Avoid twisting the catheter, as this could cause inadequate liquid flow rate.
  • Do not wrap the catheter with any wrapping.
  • Do not use the dispenser if any part is damaged or cracked or if the catheter connector appears broken, cracked or damaged in any way.
  • The flow limiter (transparent rectangle) should remain stuck to your skin. Removing the adhesive tape or allowing the flow limiter to lose contact with the skin may cause inadequate liquid flow rate.
  • Do not place hot or cold compresses on the flow limiter, as this may cause inadequate liquid flow rate.
  • Do not reconnect the dispenser if it is accidentally disconnected from the catheter/access route during medication administration, as this could cause an infection. Inform your doctor or nurse if the dispenser has been disconnected.
  • Do not bathe or shower with the dispenser or while the catheter/access route is still in place, as this could cause an infection.
  • Do not manipulate the wound dressings or the catheter/access route, as this could cause an infection.

If you use more Ropivacaína Readyfusor than you should

Since the dispenser continuously administers a defined dose of the active substance, it is very unlikely that side effects will occur as a result of using more Ropivacaína Readyfusor than you should.

If the dose received is too high, you will need special treatment and the doctor treating you is trained to handle these situations. The first symptoms that you have been given too much Ropivacaína Readyfusor are usually related to:

  • dizziness or fainting
  • numbness of the lips and around the mouth
  • numbness of the tongue
  • hearing problems
  • vision problems

To reduce the risk of serious side effects, your doctor will stop the administration of Ropivacaína Readyfusor as soon as these signs appear. This means that if you experience any of these symptoms or think you may have received too much Ropivacaína Readyfusor, tell your doctor immediately.

If you have any further questions on the use of this product, ask your doctor or nurse.

Medicine questions

Started taking the medicine and have questions?

Discuss your symptoms and treatment with a doctor online.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Important side effects to look out for

Rare, sudden-onset allergic reactions that are life-threatening (such as anaphylaxis, including anaphylactic shock) and affect 1 to 10 patients in 10,000. Possible symptoms include sudden onset rash, itching or hives, swelling of the face, lips, tongue or other parts of the body, shortness of breath, wheezing or difficulty breathing, and a feeling of loss of consciousness. If you think Ropivacaína Readyfusor is causing an allergic reaction, tell your doctor immediately.

Other possible side effects

Very common(may affect more than 1 in 10 patients)

  • Low blood pressure (hypotension). This may make you feel dizzy or faint.
  • Feeling sick (nausea)

Common(may affect up to 1 in 10 patients)

  • Tingling
  • Feeling dizzy
  • Headache
  • Slow or fast heart rate (bradycardia, tachycardia)
  • High blood pressure (hypertension)
  • Feeling sick (vomiting)
  • Difficulty urinating
  • High temperature (fever) or chills
  • Back pain

Uncommon(may affect up to 1 in 100 patients)

  • Anxiety
  • Decreased sensitivity or feeling in the skin
  • Fainting
  • Breathing difficulties
  • Low body temperature (hypothermia)
  • Some symptoms may appear if you have been given too much Ropivacaína Readyfusor (see also the previous section “If you use more Ropivacaína Readyfusor than you should”). These include seizures (convulsions), feeling dizzy or faint, numbness of the lips and around the mouth, numbness of the tongue, hearing problems, vision problems, speech problems, muscle stiffness and trembling.

Rare(may affect up to 1 in 1,000 patients)

  • Heart attack (cardiac arrest)
  • Irregular heartbeat (arrhythmias)

Frequency not known(frequency cannot be estimated from the available data)

  • Involuntary muscle movements (dyskinesia)

Possible side effects observed with other local anesthetics that may also be caused by Ropivacaína Readyfusor include

Rare(may affect up to 1 in 1,000 patients)

  • Nerve damage. This can cause permanent problems.

Reporting of side effects

If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Spanish Pharmacovigilance System for Human Use Medicines: www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of Ropivacaína Readyfusor

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the label after “EXP”. The expiry date is the last day of the month stated.

This medicine does not require any special storage conditions.

Normally, your doctor or hospital will store Ropivacaína Readyfusor and are responsible for the quality of the product. The medicine should be inspected visually before use. The solution should only be used if the solution is clear, practically free of particles and if the packaging is intact.

They are also responsible for disposing of any unused Ropivacaína Readyfusor correctly.

6. Container Contents and Additional Information

Composition of Ropivacaína Readyfusor

  • The active ingredient is ropivacaine hydrochloride. Each ml contains 2 mg of ropivacaine hydrochloride.
  • The other components are sodium chloride, sodium hydroxide solution or hydrochloric acid (for pH adjustment) and water for injectable preparations.

Appearance of the Product and Container Contents

Ropivacaína Readyfusor is a clear, colorless solution for infusion.

Ropivacaína Readyfusor infusion pump is an orange cylinder with black caps on each side. It is designed to contain a high-density polyethylene (HDPE) transparent bellows bottle with 250 ml of ropivacaine hydrochloride monohydrate solution for infusion. A catheter with a connector (luer lock) that does not contain latex is permanently attached to it.

Each container contains a Ropivacaína Readyfusor infusion pump and a transport bag. There are also containers that include a sterile latex-free multiperforated catheter (6.5 or 15 cm in length) for placement in the wound.

Marketing Authorization Holder

BioQ Pharma B.V.

Basisweg 10

1043 AP Amsterdam

Netherlands

Manufacturer

BioQ Pharma B.V.

Basisweg 10

1043 AP Amsterdam

Netherlands

Copea Pharma Europe Limited

Unit 2, Medici House, Ashbourne Manufacturing Park

Ashbourne, Co. Meath A84 KH58

Ireland

Local Representative

Euromed Pharma Spain

Av. Eduard Maristany 430-432

08918, Badalona (Barcelona)

Spain

This Medicinal Product is Authorized in the Member States of the European Economic Areaand in the United Kingdom (Northern Ireland) under the Following Names:

Austria

Ropivacain ReadyfusOR 2 mg/ml Infusionslösung im Applikationssystem

Belgium

Ropivacaine Readyfusor 2 mg/ml solution pour perfusion en système d’administration

Denmark

Ropivacaine BioQ 2 mg/ml infusionsvæske, opløsning i administrationssystem

Slovakia

Ropivacaine Readyfusor 2 mg/ml infúzny roztok v aplikacnom systéme

Spain

Ropivacaína Readyfusor 2 mg/ml solución para perfusión en sistema de administración

Finland

Ropivacaine BioQ 2 mg/ml infuusioneste, liuos, antovälineistö

France

Ropivacaine Readyfusor 2 mg/ml solution pour perfusion en système d’administration

Italy

Ropivacaina BioQ ReadyfusOR 2 mg/ml soluzione per infusione in sistema di somministrazione

Luxembourg

Ropivacaine ReadyfusOR 2 mg/ml solution pour perfusion en système d'administration

Norway

Ropivacaine BioQ 2 mg/ml infusjonsvæske, oppløsning i administreringssystem

Poland

Ropivacaine BioQ, 2 mg/ml, roztwór do infuzji w zestawie do podawania

Portugal

Ropivacaína BioQ 2 mg/ml solução para perfusão em sistema de administração

United Kingdom

(Northern Ireland)

Ropivacaine 2 mg/ml solution for infusion in administration system

Czech Republic

Ropivacaine BioQ 2 mg/ml infuzní roztok v aplikacním systému

Sweden

Ropivacaine BioQ 2 mg/ml infusionsvätska, lösning i administreringssats

Date of Last Revision of this Leaflet:09/2023

--------------------------------------------------------------------------------------------------------------------

This Information is Intended Only for Doctors or Healthcare Professionals:

Ropivacaína Readyfusor does not contain preservatives and is intended for single use.

The solution should be visually inspected before use. The solution must only be used if the solution is clear, practically free of particles, and if the container is intact.

Ropivacaína Readyfusor Infusion Pump

Ropivacaína Readyfusor infusion pump (hereinafter referred to as "dispenser") is a non-electric medication dispenser designed for use in the healthcare setting. All necessary materials for medication administration are included.

The dispenser contains a bellows bottle with 250 ml of ropivacaine hydrochloride monohydrate solution for infusion. A catheter with a connector (luer lock) is permanently attached. Neither the catheter nor the connector nor the sterile multiperforated catheter (when included in the container, see section 6) contains latex.

For wound infiltration, a multiperforated catheter will be placed in the wound during surgery according to the specific guidelines of the procedure location. The catheter (when included in the container) distributes Ropivacaína Readyfusor uniformly along the length of the wound in a 360° radius.

The liquid remaining indicator is a pair of green arrows indicating the amount of liquid left to be administered.

Graduated 250ml cylinder with volume scale, clamp, filter, connector, and transparent catheter for fluid administration

Instructions for Use

  1. Inspect the dispenser, flow limiter, and catheter for damage or tampering.

Check that the orange adhesive seal on the activation cap is intact. Check that the orange adhesive seal on the catheter plug is intact.

Do not use the dispenser if damage is observed or if there is no seal or if it is damaged.

Ampoule with white cap and safety ring, arrow pointing to breakage area with a red cross indicating not to breakAdministration device with two examples of inserted cartridges, one correct with a check mark and the other incorrect with an X

  1. Start liquid dispensing by turning the activation cap clockwise until the arrow of the orange adhesive seal aligns approximately with the arrow of the label. Significant force is required. This is normal and prevents accidental activation. The pieces inside the dispenser will move during activation.

The dispenser is activated when the green arrows of the liquid remaining indicator are visible in the window. The liquid flow can be seen upstream of the filter within seconds, but the flow will stop until the non-ventilated cap is removed.

Hands holding an auto-injector with a curved arrow indicating the direction of device rotationNeedle with bevel showing cross-sections and arrows indicating direction of insertion into a tubular container

  1. Open the catheter cap to break the safety seal.

Check that the clamp is not engaged and ensure that liquid dispensing has started by observing that liquid flows through the catheter and flow limiter.

After 1-2 minutes, the liquid will start to drip very slowly from the end of the catheter.

Hands holding a device for connection to a syringe with curved arrows indicating rotation and a straight arrow pointing to the direction

  1. Connect the dispenser catheter to the patient's access site/catheter. Do not connect to an IV catheter.
  1. Attach the flow limiter (transparent rectangle) to the patient's skin with adhesive tape. Apply the tape directly over the flow limiter as shown, away from the wound site, and ensure not to pull the catheter or alter the catheter/access site location. Finally, secure the catheter and connections with adhesive tape.

Warning: The flow limiter must remain attached to the patient's skin. If contact is lost, inadequate liquid dispensing speed may occur.

  1. Place the dispenser in the provided transport bag. The patient can wear the transport bag over the shoulder or around the waist like a belt.

Hands holding an intravenous catheter with a flow limiter attached to the skin and a solution bag nearbyHands holding an auto-injector with an indicator window and a hanging black cable

To prevent the catheter/access site from coming out, it is recommended to keep the bag attached to the patient with the dispenser inside at all times.

  1. Liquid dispensing can be observed through the dispenser window. The dispenser will administer approximately 5 ml of liquid per hour. The green arrows in the window indicate the amount of liquid remaining (in ml) in the dispenser. Periodically check through the position of the liquid remaining indicator arrows that there is no excessive flow. For symptoms of overdose, see "If you use more Ropivacaína Readyfusor than you should" (section 3).

Black medical device with screen and two extended antennas near grey human head silhouettesTransparent intravenous bag with volume graduations in milliliters from 0 to 250 ml indicating 200 ml remaining

  1. Administration is complete when the unit is empty, and the liquid remaining indicator arrows indicate zero in the window.
  1. Remove the dispenser from the patient once administration is complete.
  1. After use, discard the empty dispenser, including any unused solution, according to local requirements.

Warnings

  • The dispenser is intended for single use. Do not reuse or reconnect the dispenser.
  • The dispenser must not be sterilized in an autoclave. The fluid path in the dispensing system has already been sterilized.
  • The dispenser must not be connected to an IV catheter.
  • Twisting the catheter should be avoided, as this could cause inadequate liquid dispensing speed.
  • Do not encircle the catheter with any wrapping.
  • Do not use the dispenser if any part is damaged or cracked or if the catheter connector appears broken, cracked, or damaged in any way.
  • The flow limiter (transparent rectangle) must remain attached to the patient's skin. Removing the adhesive tape or allowing the flow limiter to lose contact with the skin may cause inadequate liquid dispensing speed.
  • Do not place hot or cold compresses over the flow limiter, as this may cause inadequate liquid dispensing speed.
  • The dispenser must not be reconnected if it is accidentally disconnected from the catheter/access site during medication administration, as this could cause an infection.
  • The patient must not bathe or shower with the dispenser or while the catheter/access site remains in place, as this could cause an infection.
  • The patient must not manipulate the wound dressings or the catheter/access site, as this could cause an infection.

Online doctors for ROPIVACAINE READYFUSOR 2 mg/mL SOLUTION FOR INFUSION IN ADMINISTRATION SYSTEM

Discuss questions about ROPIVACAINE READYFUSOR 2 mg/mL SOLUTION FOR INFUSION IN ADMINISTRATION SYSTEM, including use, safety considerations and prescription review, subject to medical assessment and local regulations.

5.0 (69)
Doctor

Tarek Agami

General medicine 11 years exp.

Dr. Tarek Agami is a general practitioner registered in both Portugal and Israel, with broad experience in family and preventive medicine. He offers online consultations for adults and children, providing personalised support for primary care needs, chronic disease management, and everyday health concerns.

Dr. Agami received clinical training and worked in leading medical institutions in Israel (Kaplan Medical Center, Barzilai Medical Center, Wolfson Medical Center) and Portugal (European Healthcare City, Viscura Internacional, Hospital Dr. José Maria Grande, Hospital Vila Franca de Xira). His approach combines international medical standards with individualised attention to each patient.

Main areas of consultation:

  • Diagnosis and treatment of acute and chronic conditions (high blood pressure, diabetes, respiratory infections, cardiovascular symptoms)
  • Evaluation of symptoms and guidance on further diagnostic testing
  • Preventive check-ups and regular health monitoring
  • Medical support during travel or after relocation
  • Treatment adjustments and lifestyle recommendations based on your personal history
Dr. Agami provides medical support for patients using GLP-1 medications (such as Ozempic or Mounjaro) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Portugal and Israel.

Dr. Agami is committed to evidence-based, patient-centred care, ensuring that each person receives trusted medical support tailored to their health goals.

Camera Book a video appointment
€69
5.0 (63)
Doctor

Nuno Tavares Lopes

Family medicine 18 years exp.

Dr. Nuno Tavares Lopes is a licensed physician in Portugal with 17 years of experience in emergency medicine, family and general practice, and public health. He is the Director of Medical and Public Health Services at an international healthcare network and serves as an external consultant for the WHO and ECDC.

  • Emergency care: infections, fever, chest/abdominal pain, minor injuries, paediatric emergencies
  • Family medicine: hypertension, diabetes, cholesterol, chronic disease management
  • Travel medicine: pre-travel advice, vaccinations, fit-to-fly certificates, travel-related illnesses
  • Sexual and reproductive health: PrEP, STD prevention, counselling, treatment
  • Weight management and wellness: personalised weight loss programmes, lifestyle guidance
  • Skin and ENT issues: acne, eczema, allergies, rashes, sore throat, sinusitis
  • Pain management: acute and chronic pain, post-surgical care
  • Public health: prevention, health screenings, long-term monitoring
  • Sick leave (Baixa médica) connected to Segurança Social in Portugal
  • IMT medical certificates for driving licence exchange
Dr. Nuno Tavares Lopes provides medical support for patients using GLP-1 medications (Mounjaro, Wegovy, Ozempic, Rybelsus) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Europe.

Dr. Lopes also provides interpretation of medical tests, follow-up care for complex patients, and multilingual support. Whether for urgent concerns or long-term care, he helps patients act with clarity and confidence.

Camera Book a video appointment
€59
5.0 (5)
Doctor

Anastasiia Hladkykh

Psychiatry 15 years exp.

Dr Anastasiia Hladkykh is a physician-psychotherapist and psychologist with over 14 years of experience working with individuals struggling with various types of addictions and their families. She provides online consultations for adults, combining medical knowledge with deep psychological support and practical tools.

Key areas of expertise:

  • Addiction treatment: alcohol and drug dependence, gambling addiction, compulsive behaviours, codependent relationships.
  • Support for families of addicted individuals, behavioural correction within the family system, guidance for maintaining remission.
  • Mental health: depression, bipolar disorder, obsessive-compulsive disorder (OCD), anxiety disorders, phobias, PTSD, generalised anxiety, emotional trauma, and the psychological impact of loss or emigration.
  • Psychoeducation: explaining complex mental health concepts in simple language, helping patients and their families understand diagnoses and treatment steps.
Therapeutic approach:
  • Client-centred, straightforward, and empathetic – focused on practical outcomes and emotional stabilisation.
  • Prescribes medications when needed, but always aims to minimise unnecessary pharmaceutical use.
  • Certified in multiple evidence-based methods: CBT, NLP (Master Practitioner), Ericksonian hypnosis, symbol drama, art therapy, and systemic therapy.
  • Each consultation results in a clear, structured plan – patients leave knowing exactly what to do next.
Experience and background:
  • Member of the German association Gesundheitpraktikerin and the NGO “Mit dem Sonne in jedem Herzen.”
  • More than 18 publications in international peer-reviewed journals, translated into several languages.
  • Volunteer work with Ukrainian refugees and military personnel at the University Clinic of Regensburg.
Camera Book a video appointment
€130
5.0 (3)
Doctor

Tomasz Grzelewski

Dermatology 21 years exp.

Dr Tomasz Grzelewski is an MD, PhD specialist in allergy, paediatrics, general practice and sports medicine, with a clinical focus on dermatology, endocrinology, allergology and sports-related health. He has more than 20 years of clinical experience and completed his medical training at the Medical University of Łódź, where he defended his PhD thesis with distinction. His doctoral research was recognised by the Polish Society of Allergology for its innovative contribution to the field. Throughout his career, he has gained extensive expertise in diagnosing and managing a wide range of allergic and paediatric conditions, including modern allergen desensitisation techniques.

For five years, Dr Grzelewski served as the Head of two paediatric departments in Poland, managing complex clinical cases and leading multidisciplinary teams. He also worked in medical centres in the United Kingdom, gaining experience across both primary care and specialist environments. With over a decade of telemedicine experience, he has provided online consultations across Europe and is valued for his clear, structured and evidence-based medical guidance.

Dr Grzelewski is actively involved in clinical programmes focused on modern anti-allergic therapies. As a Principal Investigator, he leads research projects on sublingual and oral allergen desensitisation, supporting evidence-based progress in allergy treatment for both children and adults.

In addition to his background in allergology and paediatrics, he completed dermatology studies through the Cambridge Education Group (Royal College of Physicians of Ireland) and a Clinical Endocrinology course at Harvard Medical School. This advanced training enhances his ability to manage skin manifestations of allergies, atopic conditions, urticaria, endocrine-related symptoms and complex immunological reactions.

Patients commonly seek his care for:

  • seasonal and perennial allergies
  • allergic rhinitis and chronic nasal symptoms
  • asthma and breathing difficulties
  • food and medication allergies
  • urticaria, atopic dermatitis and skin reactions
  • recurrent infections in children
  • sports-related health questions
  • general family medicine concerns
Dr Tomasz Grzelewski is known for his clear communication style, structured medical approach and ability to explain treatment options in a concise and accessible way. His multidisciplinary background across allergy, paediatrics, dermatology and endocrinology allows him to provide safe, up-to-date and comprehensive care for patients of all ages.
Camera Book a video appointment
€80

Frequently Asked Questions

Is a prescription required for ROPIVACAINE READYFUSOR 2 mg/mL SOLUTION FOR INFUSION IN ADMINISTRATION SYSTEM?
ROPIVACAINE READYFUSOR 2 mg/mL SOLUTION FOR INFUSION IN ADMINISTRATION SYSTEM requires a prescription in Spain. You can check with a doctor online whether this medicine may be appropriate for your situation.
What is the active substance in ROPIVACAINE READYFUSOR 2 mg/mL SOLUTION FOR INFUSION IN ADMINISTRATION SYSTEM?
The active ingredient in ROPIVACAINE READYFUSOR 2 mg/mL SOLUTION FOR INFUSION IN ADMINISTRATION SYSTEM is ropivacaine. This information helps identify medicines with the same composition but different brand names.
Who manufactures ROPIVACAINE READYFUSOR 2 mg/mL SOLUTION FOR INFUSION IN ADMINISTRATION SYSTEM?
ROPIVACAINE READYFUSOR 2 mg/mL SOLUTION FOR INFUSION IN ADMINISTRATION SYSTEM is manufactured by Bioq Pharma B.V.. Pharmacy brands and packaging may differ depending on the distributor.
Which doctors can assess the use of ROPIVACAINE READYFUSOR 2 mg/mL SOLUTION FOR INFUSION IN ADMINISTRATION SYSTEM online?
Doctors such as Family doctors, Psychiatrists, Dermatologists, Cardiologists, Endocrinologists, Gastroenterologists, Pulmonologists, Nephrologists, Rheumatologists, Hematologists, Infectious disease physicians, Allergists, Geriatricians, Paediatricians, Oncologists may assess whether ROPIVACAINE READYFUSOR 2 mg/mL SOLUTION FOR INFUSION IN ADMINISTRATION SYSTEM is appropriate, depending on your situation and local regulations. You can book an online consultation to discuss your symptoms and possible next steps.
What are the alternatives to ROPIVACAINE READYFUSOR 2 mg/mL SOLUTION FOR INFUSION IN ADMINISTRATION SYSTEM?
Other medicines with the same active substance (ropivacaine) include ROPIVACAINE ALTAN 10 mg/ml INJECTABLE SOLUTION, ROPIVACAINE ALTAN 2 mg/ml SOLUTION FOR INFUSION, ROPIVACAINE ALTAN 7.5 mg/ml INJECTABLE SOLUTION. These may have different brand names or formulations but contain the same therapeutic ingredient. Always consult a doctor before switching or starting a new medicine.
bg-pattern-dark

Stay informed about Oladoctor

News about new services, product updates and useful information for patients.

Follow us on social media